Quick answers
- What is Cyanocobalamin used for?
- The FDA-approved label (Nascobal, Par Health USA, LLC, March 1, 2024) says: “NASCOBAL is indicated for: Vitamin B 12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement Treatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B 12 deficiency not due to pernicious anemia Prevention of vitamin B 12 deficiency in adult patients with vitamin B 12 …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Cyanocobalamin have a boxed warning?
- No. None of the 33 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Cyanocobalamin?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Cyanocobalamin been recalled?
- FDA enforcement reports list 5 recalls of products of this medicine; the newest started July 24, 2026 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Cyanocobalamin?
- 24 companies list prescription products of Cyanocobalamin in the FDA NDC Directory, including Meitheal Pharmaceuticals Inc., HF Acquisition Co LLC, DBA HealthFirst and Gland Pharma Limited.
What Cyanocobalamin is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
NASCOBAL is indicated for: Vitamin B 12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement Treatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B 12 deficiency not due to pernicious anemia Prevention of vitamin B 12 deficiency in adult patients with vitamin B 12 …
— FDA label: Nascobal, Par Health USA, LLC, effective March 1, 2024. Read the full label on DailyMed →
The FDA has 33 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 33 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Injection, solution · Injection · Spray · Spray, metered |
|---|---|
| Route | Intramuscular · Subcutaneous · Nasal |
| Prescription products | 52 in the FDA NDC Directory |
| Brand names | Nascobal |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| cyanocobalamin 1000 ug/mL injection | Generic | $0.3281–$1.45 per mL 13 packages, lowest to highest |
| cyanocobalamin 1000 ug/mL injection, solution | Generic | $0.3281–$3.14 per mL 16 packages, lowest to highest |
| cyanocobalamin 500 ug spray | Generic | $86.43 per unit |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Meitheal Pharmaceuticals Inc.6 products
- HF Acquisition Co LLC, DBA HealthFirst4 products
- Gland Pharma Limited3 products
- Vitruvias Therapeutics3 products
- Zydus Pharmaceuticals USA Inc.3 products
- Zydus Lifesciences Limited3 products
- Asclemed USA, Inc.3 products
- Somerset Therapeutics, LLC3 products
- Plano Pharmaceuticals Inc.3 products
- Lifestar Pharma LLC3 products
- Hikma Pharmaceuticals USA Inc.3 products
- American Regent, Inc.3 products
- BluePoint Laboratories2 products
- Fresenius Kabi USA, LLC2 products
- Henry Schein, Inc.2 products
- NorthStar RxLLC1 product
- AuroMedics Pharma LLC1 product
- Sagent Pharmaceuticals1 product
- Sportpharm LLC1 product
- Lupin Pharmaceuticals, Inc.1 product
- Par Health USA, LLC1 product
- A-S Medication Solutions1 product
- SOLA Pharmaceuticals1 product
- Padagis Israel Pharmaceuticals Ltd1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021642 NASCOBAL | Endo Operations | January 31, 2005 | 10, latest December 7, 2018 2018: Labeling · 2016: Manufacturing (CMC) · 2015: Manufacturing (CMC) |
Generic approvals (15)
- ANDA080515West-Ward Pharms Int · October 20, 1971
- ANDA080737Am Regent · April 26, 1972
- ANDA080557Fresenius Kabi USA · June 20, 1973
- ANDA206503Somerset Theraps LLC · December 11, 2015
- ANDA209255H2-Pharma · December 18, 2018
- ANDA209429Somerset Theraps LLC · December 18, 2018
- ANDA212458Padagis Israel · September 9, 2020
- ANDA214390Gland · September 24, 2020
- ANDA213874Eugia Pharma · December 8, 2020
- ANDA214655Zydus Pharms · April 15, 2022
- ANDA215417Sola Pharms · April 15, 2022
- ANDA215107Sagent Pharms Inc · November 15, 2022
- ANDA210629Lupin · June 30, 2023
- ANDA217839Mankind Pharma · July 10, 2024
- ANDA214316Meitheal · November 15, 2024
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
July 24, 2026 · Class II · Ongoing · D-0792-2026
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
Cyanocobalamin injection USP, 1,000 mcg/mL, For IM or SC Use Only, packaged in a) 1 mL Multi-Dose Vial (NDC 0517-0031-01), and b) 25x1 mL Multi-Dose Vials (NDC 0517-0031-25) Rx only, AMERICAN REGENT, INC., SHIRLEY, NY 11 — American Regent, Inc.
-
July 24, 2026 · Class II · Ongoing · D-0793-2026
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
Cyanocobalamin injection USP, 10,000 mcg/10 mL (1,000 mcg/mL), For IM or SC Use Only, packaged in a) 10 mL Multi-Dose Vial (NDC 0517-0032-01) and b) 25x10 mL Multi-Dose Vials (NDC 0517-0032-25), Rx Only, AMERICAN REGENT, — American Regent, Inc.
-
April 5, 2022 · Class III · Terminated · D-0766-2022
Subpotent Drug: Out of Specification results for Assay
Cyanocobalamin Injection, USP, 1,000 mcg per mL, For IM or SC Use Only, 1 mL Vial, Rx Only, Manufactured in India, for Auromedics Pharma LLC, NDC 55150-364-01. — Aurobindo Pharma USA Inc.
-
March 15, 2021 · Class II · Terminated · D-0595-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
CYANOCOBAL Injection 1000MCG/ML 25X1ML; NDC/UPC 69680-112-25; RX; MULTI DOSE VIAL — Cardinal Health Inc.
-
September 27, 2012 · Class II · Terminated · D-0297-2015
Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.
CYANOCOBALAMIN INJECTION, USP, 1000 mcg/mL, For IM or IV Use, Multiple Dose 2 mL Vials, Rx only. APP Pharmaceuticals, LLC, Schaumburg, IL 60173. NDC: 63323-044-01. — Fresenius Kabi USA, LLC
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 309594, 861113, 861115 |
|---|---|
| SPL set ID of the quoted label | 697e0e52-c01b-4b53-9994-f79c46eb6b4f |
| FDA labels (SPL) | 33 |
| FDA applications | NDA021642, 15 ANDA |
| Active ingredients (FDA) | CYANOCOBALAMIN |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Nascobal, Par Health USA, LLC, effective March 1, 2024; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →